Wedbush downgraded Elevation Oncology (ELEV) to Neutral from Outperform with a $1.60 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELEV:
- Elevation Oncology Restructures Amid EO-3021 Discontinuation
- Elevation Oncology to discontinue development of EO-3021; Advancing EO-1022
- Buy Recommendation for Elevation Oncology: Promising Pipeline and Strong Financial Management
- Elevation Oncology’s Future in Jeopardy: Financing Challenges Threaten Product Development
- Elevation Oncology Reports 2024 Financial Results and Progress